$VRTX Recent News Stock market live blog: S&P 500 rises

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2014 at 11:20 AM

$VRTX Recent News

Stock market live blog: S&P 500 rises to intraday record after confidence, home-sales data < 1 min ago - blogs.marketwatch.com
Vertex soars on trial success; Walgreen falls 44 min ago - Ben Eisen
U.S. stocks edge up; S&P 500 hits record 56 min ago - Anora Mahmudova
Vertex Pharmaceuticals shares skyrocket 50% 9:32 a.m. Today - Sue Chang
Vertex’ late-stage Cystic Fibrosis trial meets goals 7:58 a.m. Today - Anna Prior
Vertex Pharmaceuticals soars 46% on treatment trial 7:32 a.m. Today - Ben Eisen
Vertex reports successful Phase 3 trial of cystic fibrosis treatment 7:22 a.m. Today - Ciara Linnane
Vertex reports successl Phase 3 trial of cystic fibrosis treatment 7:11 a.m. Today - Ciara Linnane
E-Trade, Schwab up on HFT hearing; Tesla extends gains 3:53 p.m. June 17, 2014 - Ben Eisen
Covidien surges on sale; Yahoo drops on Alibaba results 3:48 p.m. June 16, 2014 - Saumya Vaishampayan
Charting the approach of S&P 2,000 12:28 p.m. June 10, 2014 - Michael Ashbaugh
Charting the approach of S&P 2,000 12:09 p.m. June 10, 2014 - Michael Ashbaugh
U.S. benchmarks flatline ahead of ECB policy directive 10:08 a.m. June 4, 2014 - Michael Ashbaugh
Dollar Tree rallies; Lorillard in talks with Reynolds 3:42 p.m. May 22, 2014 - Saumya Vaishampayan
3 lesser-known dividend stocks for a rocky summer 6:00 a.m. May 8, 2014 - Jeff Reeves
LinkedIn shares decline after-hours on results 6:40 p.m. May 1, 2014 - Wallace Witkowski
After Hours: LinkedIn shares decline following results 5:19 p.m. May 1, 2014 - blogs.marketwatch.com
Edwards soars on injunction; Citi rallies on results 3:49 p.m. April 14, 2014 - Saumya Vaishampayan
Herbalife sinks on probe fears; Zoe’s surges on debut 4:36 p.m. April 11, 2014 - Ben Eisen
Anadarko up on settlement; Amazon falls as Fire fizzles 3:54 p.m. April 3, 2014 - Ben Eisen

Dow Sets Sights on 17000 4 min ago - The Wall Street Journal Interactive Edition
Why Vertex Pharmaceuticals (VRTX) Stock Hit a One-Year High Today 10:10 a.m. Today - TheStreet.com
The Seasonally Quiet Period - Ahead of Wall Street 10:06 a.m. Today - Zacks.com
Vertex's Cystic Fibrosis Treatment Shows Promise 9:25 a.m. Today - The Wall Street Journal Interactive Edition
Vertex Rockets On Drug Combo Success 8:19 a.m. Today - Seeking Alpha
Successful Phase 3 results for CF drug combo 8:06 a.m. Today - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Off To A Strong Start In Pre-Market Activity 7:47 a.m. Today - TheStreet.com
Why Are Vertex Pharmaceuticals Up More Than 50 Percent? 7:27 a.m. Today - benzinga.com
Vertex Pharma Cystic Fibrosis Combo Therapy Hits Key Endpoints in Two Pivotal Trials 7:25 a.m. Today - TheStreet.com
Dow 30 Stock Roundup: Intel Ups Q2 Guidance, Boeing Set to Win China Eastern's $7.4B Order - Analyst Blog 1:59 p.m. June 20, 2014 - Zacks.com
Vertex Pharmaceuticals-Johnson & Johnson Collaborate on Flu Drug - Analyst Blog 5:00 p.m. June 19, 2014 - Zacks.com
3 Stocks Pulling The Drugs Industry Downward 1:03 p.m. June 18, 2014 - TheStreet.com
Vertex licenses flu drug candidate to Janssen 9:15 a.m. June 18, 2014 - Seeking Alpha
Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A 9:07 a.m. June 18, 2014 - CNW Group
'Mad Money' Lightning Round: Sell, Sell, Sell Exxon Mobil 6:00 a.m. June 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market 8:31 p.m. June 17, 2014 - TheStreet.com
Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog 5:00 p.m. June 17, 2014 - Zacks.com
Vertex Shares Hit Hard On Trial Concerns 12:39 p.m. June 16, 2014 - benzinga.com
Benzinga's Top #PreMarket Losers 7:16 a.m. June 16, 2014 - benzinga.com
Analyst Goes to Sweden, Returns Home Predicting Vertex CF Drug Failure 7:01 a.m. June 16, 2014 - TheStreet.com

Cystic Fibrosis Foundation Applauds Successful Phase 3 Results of Ivacaftor (Kalydeco™) and Lumacaftor (VX-809) Drug Combination for People with Two Copies of F508del Mutation of Cystic Fibrosis 42 min ago - PR Newswire - PRF
Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation 7:00 a.m. Today - BusinessWire - BZX
Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza 8:30 a.m. June 18, 2014 - BusinessWire - BZX
Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A 8:30 a.m. June 18, 2014 - PR Newswire - PRF
Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis 5:15 p.m. June 16, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Vertex Pharmaceuticals Incorporated to Contact the Firm Before the Lead Plaintiff Deadline in Class Action Lawsuit -- VRTX 9:45 p.m. June 13, 2014 - GlobeNewswire
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX 4:32 p.m. June 13, 2014 - GlobeNewswire
Kirby McInerney LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals, Inc. 1:18 p.m. June 12, 2014 - BusinessWire - BZX
Kirby McInerney LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals, Inc. 12:12 p.m. June 12, 2014 - BusinessWire - BZX
Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference 9:02 a.m. June 12, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex Pharmaceuticals Incorporated To Contact The Firm Before The Lead Plaintiff Deadline In Class Action Lawsuit 3:05 p.m. June 6, 2014 - BusinessWire - BZX
Biotech Equities Ahead of Market -- Research on Vertex Pharma, NewLink Genetics, ImmunoGen, and Synta Pharma 7:20 a.m. June 5, 2014 - PR Newswire - PRF
Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation 8:02 a.m. June 4, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Investigation on Behalf of Vertex Pharmaceuticals Incorporated Investors Announced by Law Offices of Howard G. Smith 5:32 p.m. June 3, 2014 - BusinessWire - BZX
Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10 4:01 p.m. June 3, 2014 - BusinessWire - BZX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vertex Pharmaceuticals Incorporated - VRTX 3:24 p.m. June 3, 2014 - PR Newswire - PRF
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX 11:47 a.m. May 30, 2014 - GlobeNewswire
SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Vertex Pharmaceuticals Incorporated to Contact the Firm Before the Lead Plaintiff Deadline in Class Action Lawsuit -- VRTX 4:09 p.m. May 29, 2014 - GlobeNewswire
Vertex Pharmaceuticals, Incorporated: Scott+Scott, Attorneys at Law, LLP Files Shareholder Class Action Against Vertex Pharmaceuticals Incorporated -- VRTX 1:03 p.m. May 28, 2014 - GlobeNewswire
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiation Oncology Text Earns Doody's 2026 Nod

Recognition in Radiation Oncology In the rapidly advancing arena of radiation oncology, staying current is no small feat. But here's a feather in the cap of one publication doing just that: Fundamentals of Radiation Oncology: Physical, Biological, and Clinical Aspects, 4th Edition. This resource has made quite the splash by snagging a spot on the 2026 Doody's Core Titles...

Curis Prepares for Q3 2026 Results Amid Tough Sector Trends

All Eyes on Curis as Q3 Financials Loom Just when you think you’ve seen it all in this wild biotech ride, Curis, Inc. (NASDAQ: CRIS) is prepping to roll out their third quarter financial and operating results. Circle your calendars for November 12, 2026, because the clock’s ticking down to their 4:00 p.m. ET announcement, swiftly followed by a conference call at 4:30...

Home Insurance Depreciation and What it Means for You

A Deep Dive into Depreciation's Impact on Home Insurance Folks, if you haven't battled the insurance beast, you're missing out on an unholy mess. Let's talk about something that's been quietly gnawing at homeowners’ wallets—depreciation in home insurance claims. Peggy Schneider, an insurance guru from Kalispell, Montana, lays it all out in HelloNation, and I'm here to...

FDA Greenlights Halozyme's Cancer Treatment Breakthrough

FDA's Seal of Approval: A Game Changer Well, folks, here's a twist in the story of cancer treatment with FDA giving a nod to RYBREVANT FASPRO. Johnson & Johnson's latest offering, fueled by Halozyme's groundbreaking ENHANZE technology, just snagged accelerated approval. We're not just talking any old treatment here; it's a dual-targeted therapy for head and neck cancer...

Birth Registration Revolution: OSIA Interoperability Demo

Bringing Birth Registration into the 21st Century Alright, let's cut through the fog. If you ask most folks about their birth certificates, you'd hear tales of tattered paper and government office runs. What if I told you this vital piece of paper could be reborn altogether? That's what the Secure Identity Alliance is up to with their OSIA Live Interoperability Demo at...

TELUS Boosts Board with Strategic Executive Appointments

New Faces on the TELUS Board: Shaping the Future Alright, investors, here's the scoop straight from the trenches: TELUS (TSX:TU) is shaking things up at the top. Marc Allera and Bill Thomas are stepping into the fray as the newest members of the board, effective January 1, 2027. If you're not familiar with these names, it's time to tune in because they've got the chops to...

Encompass Health Faces Uncertain Future with Sea Pines

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Bowling Makes a Strike at Macy's 100th Parade in NYC

Rolling with Tradition: Bowling at Macy's Parade Back in the day, bowling wasn't exactly the sport making headlines. But times, they change. Here we are in the thick of things, witnessing Go Bowling getting its moment in the spotlight during the historic 100th Macy's Thanksgiving Day Parade®. It's not about raking in the dough or hitting some stocks; it’s about...

PPL Reports Strong Q3; Long-Term EPS Growth Up

Solid Earnings in a Challenging Market Anytime you start hearing a company like PPL boasting about their quarterly earnings, it's time to sit up straight and pay attention. The utility giant didn’t just match expectations, they beat 'em, clocking in with $0.54 per share in ongoing earnings for Q3 2026, up from $0.48 the previous year. Not a bad step forward if you ask...

Tucows Shows Progress in Q3 2026 Amidst Net Loss

Q3 Snapshot: Balancing Act at Tucows Man, if there's one thing you can count on from Tucows, it's that they'll shuffle the deck just when you're getting comfortable. Here in the third quarter of 2026, they've managed a decent juggling act. Their unaudited numbers show consolidated net revenue ticking up 1.4% from last year, rounding out at a cool $100 million. That's...